MaaT Pharma

Focus: MaaT Pharma is a France-based public microbiome correction specialist focusing on gastroenterology and immunology indications through fecal microbiota transplantation and capsule-based therapies. The company operates at mid-scale with 201-500 employees and is advancing a diverse pipeline across multiple therapeutic areas.

Gastroenterology

Profile data last refreshed 20h ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Employees

201-500

Open Jobs

About MaaT Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow MaaT Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Biological samples collection of blood and feces

Bone and Joint Infection

N/A

Clinical Trials (1)

NCT03011502InterventiOnal Study of Bone and Joint Infections Related Gut dysbiosIS

N/A

Help build intelligence for MaaT Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneer in microbiome-based therapeutics with a rare clinical modality offering differentiated career exposure in an emerging field
Diverse pipeline spanning 11+ programs across Phase 1-3, with MaaT013 in Phase 3 for acute intestinal GVHD offering near-term catalysts
European public company base (Lyon, France) provides stability as a listed entity while maintaining biotech-scale innovation culture

Watch Out For

Zero currently active job openings signals potential headcount freeze or organizational consolidation
Pipeline heavily weighted toward early-stage programs (Phases 1-2) with only one Phase 3 asset, creating clinical trial risk and lengthy value realization timeline
Complete absence of financial data (revenue, cash position, R&D spend) makes it impossible to assess runway, profitability, or investment capacity

Generated by Claude from MaaT Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Blood and stool sample collection

Intestinal GVHD

N/A

Clinical Trials (1)

NCT05017688Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013

N/A

MaaT013

Acute Graft Versus Host Disease in Intestine

N/A

Clinical Trials (1)

NCT04768907Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease

N/A

MaaT033

Amyotrophic Lateral Sclerosis

PHASE_1

Clinical Trials (1)

NCT05889572Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis

Phase 1

MaaT033 capsule

Hematologic Diseases

PHASE_1

Clinical Trials (1)

NCT04150393Safety and Tolerability Evaluation of MaaT033

Phase 1

Autologous Fecal Microbiota Transplantation

Leukemia, Myeloid, Acute

PHASE_1_2

Clinical Trials (1)

NCT02928523PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients

Phase 1/2

fecal microbiota transfer

Fecal Microbiota Transplantation

PHASE_2

Clinical Trials (1)

NCT03359980Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer

Phase 2

Pooled allogeneic fecal microbiotherapy

Transplant Complication

PHASE_2

Clinical Trials (1)

NCT05762211Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

Phase 2

MaaT033 capsule

NSCLC (Advanced Non-small Cell Lung Cancer)

PHASE_2

Clinical Trials (1)

NCT07001618Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

Phase 2

fecal microbiota transfer

Intensive Care Units

PHASE_2

Clinical Trials (1)

NCT03350178Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY

Phase 2

MaaT013

Acute Graft Versus Host Disease in Intestine

PHASE_3

Clinical Trials (1)

NCT04769895MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients